Pluri (NASDAQ:PLUR) Shares Up 4.7%
Pluri (NASDAQ:PLUR) Shares Up 4.7%
Pluri Inc. (NASDAQ:PLUR – Get Rating)'s share price shot up 4.7% on Thursday . The stock traded as high as $0.92 and last traded at $0.91. 111,089 shares were traded during trading, a decline of 76% from the average session volume of 457,724 shares. The stock had previously closed at $0.87.
納斯達克:PLUR-GET評級公司股價週四飆升4.7%,盤中一度漲至0.92美元,最新報0.91美元。盤中成交量為111,089股,較457,724股的平均成交量下降了76%。該股此前收盤報0.87美元。
Pluri Stock Performance
普魯裡股票表現
The company has a debt-to-equity ratio of 0.77, a current ratio of 9.91 and a quick ratio of 9.91. The business's 50 day simple moving average is $0.76.
該公司的債務權益比為0.77,流動比率為9.91,速動比率為9.91。該業務的50日簡單移動均線切入位為0.76美元。
Institutional Trading of Pluri
普魯裡的機構交易
Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Pluri in the 3rd quarter worth $28,000. Values First Advisors Inc. bought a new stake in shares of Pluri in the 3rd quarter worth $38,000. Green Alpha Advisors LLC bought a new stake in shares of Pluri in the 3rd quarter worth $44,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Pluri in the 3rd quarter worth $81,000. Institutional investors own 8.75% of the company's stock.
對沖基金和其他機構投資者最近調整了對該公司的持股。建恩街集團在第三季度購買了價值2.8萬美元的Pluri新股。Values First Advisors Inc.在第三季度購買了價值3.8萬美元的Pluri新股。Green Alpha Advisors LLC在第三季度購買了價值44,000美元的Pluri新股。最後,復興科技有限責任公司在第三季度購買了價值8.1萬美元的Pluri新股。機構投資者持有該公司8.75%的股份。
About Pluri
關於Pluri
Pluri Inc, a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation.
Pluri Inc.是一家生物技術公司,專注於開發基於胎盤的細胞治療產品,用於治療炎症、肌肉損傷和血液疾病。該公司開發以胎盤擴大(PLX)為基礎的細胞治療產品,包括針對髖部骨折手術後肌肉恢復的PLX-PAD處於第三階段臨床試驗;與特拉維夫Sourasky醫學中心合作治療激素難治性移植物抗宿主疾病的I/II階段臨床試驗;以及治療與新冠肺炎相關的急性呼吸窘迫綜合徵的第二階段臨床試驗和骨髓移植後不完全恢復的第一階段臨床試驗。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Pluri (PLUR)
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- 免費獲取StockNews.com關於Pluri的研究報告(PLUR)
- 這就是為什麼達科電子在一天內下跌了40%
- 是時候在Gamestop上認輸了嗎?
- 為什麼你應該避免Carvana,即使它可以避免破產
- 投資者是否聽到了Spotify下跌趨勢的終結?
- 美聯儲軸心的問題不是是否,而是何時,這是為什麼
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pluri Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pluri和相關公司的最新新聞和分析師評級的每日簡要摘要。